Merck prevails in Fosamax liability suit; Roche chief scouting for buyouts, rights;

  @FiercePharma: Bayer to cut 4,500 jobs in global overhaul. Story | Follow @FiercePharma

> Merck won one another of several bellwether product-liability cases involving its osteoporosis drug Fosamax. Item

> Roche is looking for opportunities to make small-to-medium-sized acquisitions or to gain rights to new products, SonntagsZeitung reported, citing CEO Severin Schwan. News

> Genzyme expects to meet a Nov. 28 deadline to move finishing and filling operations for U.S. products from its Allston, Massachusetts plant. Article

Special Report: Top 5 Game-Changing Drug Delivery Technologies. Report

> French drugmaker Sanofi-Aventis's bid for U.S. biotech group Genzyme would not affect Sanofi's dividend policy in the short term, CFO Jerome Contamine said. Report

> China's market for diabetes-related drugs will almost triple to $2 billion over the next decade, spurred by increased prevalence of the disease, Datamonitor Group said. Story

Special Report: Pharma manufacturing consent decrees: 16 black holes. Item 

> Indian generics maker Dr. Reddy's Laboratories said it has launched a generic version of AstraZeneca's asthma tablet Accolate in the U.S. after receiving a favorable court decision. Article

> Globalization is the main challenge to drug supply chain security, according to USP scientist Desmond Hunt, who says greater collaboration is the key to maintaining product integrity. News

Special Report: Biggest Battles in Biopharma. Report

Biotech News

 @FierceBiotech: GSK: Not interested in Gemzyme deal. Story | Follow @FierceBiotech

> Regeneron AMD drug beats Lucentis on dosing in Phase III. Report 

> Celldex touts promise of PhII brain cancer vaccine data. News 

> Genzyme proffers milestone-based deal to potential suitors. Article 

Biotech IT News

> Pfizer recruits academia as research partner. Story

> iPhone apps aid clinic workflow, management. Report

> Researchers tap online forums for subjects, insights. Article 

> Biolex reveals ePRO surprise, selection process. Item 

> Studies: a "yea" and a "nay" for pharma Internet sites. News

> Cloud indecision has its price. Article 

And Finally... Removing cough and cold medicines for very young children from store shelves led to a big decline in emergency room visits for bad reactions to the drugs, government research found. Report

Suggested Articles

Bluebird Bio has overcome a manufacturing hiccup that looked like it would delay its gene therapy launch in Europe until next year.

Lilly's top U.S. executive is on his way out. Enrique Conterno, who also heads up Lilly's global diabetes business, will step down at year's end.

GlaxoSmithKline, Pfizer, Sanofi and Boehringer Ingelheim are facing lawsuit claims that they failed to test for possible carcinogens in Zantac.